There were 46 press releases posted in the last 24 hours and 154,438 in the last 365 days.

Global Pharmaceuticals Market Report 2018-2023: Focus on Women's Health - Pipeline Assesment, Technologies Overview and Key Driving Factors & Opportunities

/EIN News/ -- Dublin, July 13, 2018 (GLOBE NEWSWIRE) -- The "Pharmaceuticals for Women's Health: Global Markets to 2023" report has been added to ResearchAndMarkets.com's offering.

While women's health encompasses several health issues, this report will focus on menopause-related disorders, postmenopausal osteoporosis, endometriosis, polycystic ovarian syndrome and pregnancy disorders.

Report includes:

  • Detailed overview of the global markets for pharmaceuticals for women's health
  • Country specific data and analysis for United States, Mexico, Germany, U.K., France, China, India, Japan, Middle East and Africa
  • A look at the regulatory environment which has been a driving force in the drug development industry
  • Information on competitor initiatives, and information with regard to demand for specialty chemicals used to develop new products and for new applications
  • A relevant patent analysis within the sector
  • Comprehensive company profiles of major Players in the Market including AbbVie Inc., Allergan PLC, Amgen Inc., Bayer Ag., Eli Lilly and Company, Johnson & Johnson Inc., Novo Nordisk and Pfizer Inc.

Key Topics Covered

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related Reports

Chapter 2 Summary and Highlights

Chapter 3 Technologies and Global Markets Overview

  • Disease Overview and Definitions
  • Market Driving Factors and Opportunities
  • Aging Female Population
  • Government Involvement and Increased Funding
  • Increasing Awareness Regarding Women's Disorders and Treatments
  • Market Restraints
  • Poor Diagnosis
  • Availability of Alternate Treatment Options and Lifestyle Changes
  • Unavailability of Novel Treatments
  • High Cost of Treatment

Chapter 4 Pipeline Assessment and Analysis

  • List of Drugs in Pipeline
  • Overview of Osteoporosis Drug Development Pipeline
  • Late-stage Pipeline Drugs
  • Elagolix (AbbVie Inc.)
  • Vilaprisan (Bayer AG)
  • Evenity (Amgen Inc.)
  • Relugolix (Myovant Sciences)
  • Proellex (Repros Therapeutics)
  • Esmya (Allergan Inc.)
  • TX-004HR (TherapeuticsMD, Inc.)
  • TX-001HR (TherapeuticsMD, Inc.)

Chapter 5 Regulatory Structure

  • Overview of Regulations
  • United States
  • Canada
  • Europe
  • Japan
  • Overview of Pricing and Reimbursement
  • United States
  • Canada
  • Europe
  • Japan

Chapter 6 Market Breakdown by Women's Health Disorders

  • Introduction
  • Menopause-Related Diseases
  • Overview
  • Symptoms
  • Risk Factors
  • Epidemiology and Economic Burden
  • Diagnosis
  • Treatments
  • Market Size and Forecasts
  • Postmenopausal Osteoporosis
  • Overview
  • Epidemiology and Economic Burden
  • Diagnosis
  • Treatments
  • Market Size and Forecasts
  • Endometriosis
  • Overview
  • Epidemiology and Economic Burden
  • Diagnosis
  • Treatments
  • Market Size and Forecasts
  • Polycystic Ovary Syndrome (PCOS)
  • Overview
  • Reducing the Risk of PCOS
  • Epidemiology and Economic Burden
  • Diagnosis
  • Treatments
  • Market Size and Forecasts
  • Pregnancy Disorders and Management
  • Overview
  • Market Size and Forecasts
  • Others
  • Overview
  • Market Size and Forecasts

Chapter 7 Market Breakdown by Region

  • Introduction
  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia-Pacific
  • South America
  • Middle East and Africa

Chapter 8 Competitive Landscape and Key Developments

  • Market Players and Strategy
  • Patent Analysis
  • List of Key Patents
  • Key Developments
  • Mergers and Acquisitions
  • Development of Innovative Products/Novel Product Launch
  • Agreements, Collaborations & Partnerships
  • Key Products

Chapter 9 Company Profiles

  • ABBVIE INC.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • ALLERGAN PLC.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • AMGEN INC.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • BAYER AG
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • DAIICHI SANKYO COMPANY. LTD.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • ELI LILLY AND COMPANY
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • JOHNSON & JOHNSON INC.
  • Company Overview
  • Product Information
  • Financials
  • MERCK & CO. INC.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • MERCK KGAA
  • Company Overview
  • Product Information
  • NOVO NORDISK
  • Company Overview
  • Product Information
  • Financials
  • PFIZER INC.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials

Chapter 10 Appendix

  • Abbreviations Used in the Report

For more information about this report visit https://www.researchandmarkets.com/research/fp3k82/global?w=12



CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Women's Health

Primary Logo